Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Incyte Corporation, Jazz Pharmaceuticals, and Mallinckrodt Pharmaceuticals, Inc.

Advances in™ Transplant: Assessing the Impact of Recent Advances for the Management of aGvHD


Release Date: May 31, 2019
Expiration Date: May 31, 2020
Media: Internet - based

Activity Overview

Acute GvHD (aGvHD) occurs in 30% to 70% of patients receiving allogeneic stem cell transplants to treat hematologic malignancies. The ability to diagnose aGvHD in a timely manner, or to even predict aGvHD before clinical manifestations, along with the accurate stratification of patients with aGvHD, are critical steps to improve the treatment outcomes of these patients. Many novel biomarkers that may help achieve these goals have been studied recently. Similarly, expanding knowledge of pathophysiology of aGvHD has helped identify new targets, which, in turn, has led to the development of several novel investigational therapies that are showing promising efficacy in both upfront and steroid-refractory settings. As clinical options continue to emerge and evolve, clinicians must keep up-to-date on the cutting-edge data that continue to shape the best options for care in these patient populations.

In this activity, Advances in™ Transplant: Assessing the Impact of Recent Advances for the Management of aGvHD, you will explore the treatment approach, sequencing, and management decisions recommended by expert faculty. Leslie S. Kean, MD, PhD, is director of the Stem Cell Transplant Center at Dana-Farber/Boston Children’s Hospital and is Robert A. Stranahan Professor of Pediatrics, Harvard Medical School, Boston, MA. James L. M. Ferrara, MD, DSc, is Ward-Coleman Chair of Cancer Medicine and director of the Hematologic Malignancies Translational Research Center at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and codirector of the Mount Sinai Acute GVHD International Consortium (MAGIC), New York, NY. They will present their perspectives on how you can apply recent trial findings to help you provide personalized, optimal care for your patients. Case studies are used to illustrate these practices in a real-world setting. You will learn about the most current and novel testing methodologies for detecting and treating aGvHD, and how to integrate novel clinical approaches into current clinical practices.

Benefits of Participating

At the conclusion of this activity, you should be better prepared to:

  • Assess the pathogenesis of acute graft-versus-host disease (aGvHD) and the guidelines to assess, stage, and manage patients with this condition.
  • Outline preventive strategies to deter the development of aGvHD in patients undergoing hematopoietic stem cell transplantation.
  • Discuss novel biomarkers that can facilitate the identification of acute and chronic GvHD and the probability of treatment response.
  • Evaluate the clinical benefits and safety of novel and emerging agents and regimens to decrease risk, as well as to treat aGvHD.

CME Activity Table of Contents

  • Module 1: Understanding aGvHD: Significance, Diagnostic Challenges, and Novel Diagnostic Strategies
  • Module 2: Novel Advances in aGvHD Treatment and Prevention
  • Module 3: Integrating Novel Therapies Into Clinical Practice: How to Select a Novel Agent for aGvHD and the Importance of Directing Patients to Clinical Trials

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation, Jazz Pharmaceuticals, and Mallinckrodt Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Examine recent developments in the pathogenesis of acute graft-versus-host disease (aGvHD) and the mechanistical rationale supporting the use of novel therapies.
  • Discuss novel biomarkers that can facilitate the identification of aGvHD and the probability of treatment response.
  • Review the clinical benefits and safety of novel and emerging agents and regimens for the treatment of patients with aGvHD.
  • Assess recent clinical trial evidence in the context of emerging treatment paradigms and strategies in the management of patients with aGvHD.

Faculty, Staff, and Planners’ Disclosures

James L. M. Ferrara
James L. M. Ferrara, MD, DSc
Ward-Coleman Professor of Cancer Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Consultant: Viracor; Intellectual property: royalties from a patent for acute GVHD biomarkers licensed to Viracor.

Leslie S. Kean
Leslie S. Kean, MD, PhD
Director, Stem Cell Transplantation Program
Division of Hematology/Oncology, Boston Children’s Hospital
Department of Pediatric Oncology, Dana-Farber Cancer Institute
Robert A. Stranahan Professor of Pediatrics, Harvard Medical School

Disclosures: Grant/Research: Regeneron, Bristol-Myers Squibb, Kymab Ltd, Bluebird Bio, Magenta, Jazz; Consultant: Forty Seven, Inc, EMD Serono, Kymab Ltd.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By